Capula Management’s Cencora COR Stock Holding History

Capula Management’s Portfolio COR Stock Details COR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,910	Closed	-$482K	–	733
2022 Q4	$482K	Buy	2,910 +1,300	+81%	+$205K	0.01%	586
2022 Q3	$218K	Buy	+1,610	New	+$231K	﹤0.01%	574
2021 Q3	–	Sell	-2,327	Closed	-$266K	–	888
2021 Q2	$266K	Buy	+2,327	New	+$275K	﹤0.01%	604

Other funds holding COR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capula Management's COR Position: Q1 2023 in Review

Capula Management sold out of Cencora (COR) in Q1 2023, closing a stake of 2,910 shares — an estimated $482K sold.

Capula Management first reported a position in COR in Q2 2021 and held it in 3 quarters. The position peaked at $482K in Q4 2022. 943 funds tracked by Wall St. Rank hold COR as of Q1 2023.

Capula Management reported no remaining Cencora position as of Q1 2023 after selling out during the quarter.
Capula Management sold 2,910 Cencora shares in Q1 2023, an estimated $482K.
Capula Management first reported a position in Cencora in Q2 2021 and held it in 3 quarters.
Capula Management's Cencora position peaked at $482K in Q4 2022.
943 funds tracked by Wall St. Rank held Cencora as of Q1 2023.

Based on Capula Management's 13F filing for Q1 2023, filed 10 May 2023.